Literature DB >> 3185956

Antigenic characteristics of neurofibrillary tangles in progressive supranuclear palsy.

P G Galloway1.   

Abstract

The antigenic components of neurofibrillary tangles in the basal forebrain and brainstem were studied in 4 cases of progressive supranuclear palsy (PSP) at the light and electron microscopic levels, using antibodies to neurofilaments (in the phosphorylated and non-phosphorylated forms); the high, middle and low molecular weight neurofilament subunits; ubiquitin; the microtubule associated proteins MAP1, MAP2 and tau; isolated Alzheimer paired helical filaments and to tubulin, in the tyrosinated and detyrosinated forms. Although PSP neurofibrillary tangles appear to have most antigenic sites in common with those of Alzheimer disease, PSP tangles share epitopes with tyrosinated and detyrosinated tubulin, which has not been demonstrated in Alzheimer neurofibrillary tangles.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3185956     DOI: 10.1016/0304-3940(88)90759-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  4 in total

1.  Filaments of Lewy bodies contain insoluble cytoskeletal elements.

Authors:  P G Galloway; P Mulvihill; G Perry
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

2.  Induction of epitopes associated with neurofibrillary tangles in clonal mouse neuroblastoma (S20Y) cells.

Authors:  L Ko; K F Sheu; O Young; J P Blass
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

3.  Neurofibrillary tangles in the neurons of spinal dorsal root ganglia of patients with progressive supranuclear palsy.

Authors:  M Nishimura; Y Namba; K Ikeda; I Akiguchi; M Oda
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

4.  The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities.

Authors:  Saar Oz; Yanina Ivashko-Pachima; Illana Gozes
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.